Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer-A Retrospective Cohort Study of 161,492 Patients in Germany.

Niklas GremkeSebastian GriewingArturas KadysKarel KostevUwe WagnerMatthias Kalder

Published in: Cancers (2023)

Across all age groups, the cumulative incidence of antiresorptive drug prescriptions was higher in patients with BC treated with AI than those receiving TAM. Denosumab was most frequently used as an antiresorptive drug in patients treated with AI, while alendronate was administered more often in patients treated with TAM.

Keyphrases

artificial intelligence
adverse drug
risk factors
emergency department
drug induced
young adults
combination therapy
postmenopausal women